Astria Therapeutics' (ATXS) shares were up nearly 3% in recent Friday trading after JMP Securities initiated the company's stock at outperform.
This comes days after the company started its phase 1a clinical trial in healthy subjects of STAR-0310, a potential treatment for atopic dermatitis. Early proof-of-concept results are expected in Q3.
Trading volume stood at over 162,000 shares against a daily average of about 323,000 shares.
Price: 7.70, Change: +0.21, Percent Change: +2.80
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。